Tracers / [211At]At-meta-astatobenzylguanidine
[211At]At-meta-astatobenzylguanidine
Also written as [At-211]meta-astatobenzylguanidine
- Radionuclide
- At-211 t½ 431 min
- Modality
- Therapy
- Production route
- —
- Stage
- first-in-human clinical trial
- Syntheses indexed
- 3
What it is
- Compound class
- meta-astatobenzylguanidine (MABG), an alpha-emitting radiolabeled guanidine analogue
- Target / mechanism
- —
- Clinical application
- Targeted alpha therapy for pheochromocytoma or paraganglioma (PPGL) PMID 38805424
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | — | — | — | — | 38805424 2024 PLoS One Investigational drugs (Fig 2) are manufactured in-house by the Advanced Clinical Research Center, in the Fukushima Global Medical Science Center at Fukushima Medical University. |
| — | — | — | — | — | — | 34897556 2021 EJNMMI Phys |
| — | — | — | — | — | — | 42342363 2026 Biol Pharm Bull |
Need this precursor?We can point you to suppliers for [211At]At-meta-astatobenzylguanidine, or handle the enquiry for you.
Get in touchNotes
Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 3 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Stage set/updated at stage 23 from PMID 38805424: 'We are currently conducting an investigator-initiated first-in-human clinical trial to evaluate the pharmacokinetics, safety, and efficacy of [211At] MABG.'. | Stage 28: added indication(s) onc-ppgl from consolidated missing-rubric review.